An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Legend Biotech Announces Participation in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) will participate in upcoming investor conferences: Jefferies Healthcare Conference on June 7, 2023, and Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023.
Positive
Legend Biotech will have the opportunity to showcase its novel therapies at the investor conferences, potentially attracting new investors and increasing stock price.
Negative
No negative takes found.
SOMERSET, N.J.--(BUSINESS WIRE)--
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the upcoming investor conferences:
Event: Jefferies Healthcare Conference
Location:New York, NY Fireside Chat Date & Time: Wednesday, June 7, 2023 at 1:30pm ET
Presenter: Ying Huang, Ph.D., CEO
Event: Goldman Sachs 44th Annual Global Healthcare Conference
Location:Dana Point, CA Fireside Chat Date & Time: Wednesday, June 14, 2023 at 8:00am PT
Presenter: Ying Huang, Ph.D., CEO
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o
